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INTRODUCTION
In the past several years it has become evident that inflammation contributes to the elevation of blood pressure and end organ damage in numerous experimental models of hypertension.
In mice lacking the recombinase-activating gene (RAG-1 -/-mice), which lack all lymphocytes, the hypertensive responses to angiotensin II (ang II), deoxycorticosterone acetate-salt challenge, norepinephrine and emotional stress are blunted. Mice with severe combined immunodeficiency are also protected against hypertension. 4 Likewise, deletion of the RAG-1 gene in Dahl salt-sensitive rats blunts their hypertension and renal damage upon salt feeding. 5 T cells with an effector phenotype infiltrate the kidney and periadventitial tissues, where they release inflammatory cytokines, including interleukin 17A, interferon-γ (IFN-γ) and tumor necrosis factor α (TNF-α) that in turn alter renal and vascular function and participate in end-organ damage. [6] [7] [8] Genetic deletion of these cytokines or treatment with their specific antagonists blunts hypertension and its attendant end-organ dysfunction.
Despite the overwhelming evidence that inflammation and immunity contribute to hypertension in these experimental models, there is a paucity of information to suggest that hypertension or the factors present in the hypertensive milieu lead to T cell activation in humans. In the present study, we addressed this issue using several approaches. First we used a unique animal model, the bone/liver/thymus (BLT) humanized mouse to determine whether Ang II-induced hypertension is associated with T cell activation and infiltration into key target tissues. Second, we examined the direct effects of ang II on human T cell activation and human dendritic cell (DC) function in culture. Finally, we analyzed the phenotype of circulating T cells in humans with and without hypertension.
METHODS

BLT mice:
The Vanderbilt University Institutional Animal Care approved all experiments. Mice were cared for in accordance with the Guide for the Care and Use of Laboratory Animals.
Bone marrow, liver, thymus (BLT) mice were produced on a NSG (NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ) background as previously described. 9, 10 Twelve to fourteen weeks after immune reconstitution, osmotic minipumps (Alzet, model 2002) were implanted subcutaneously for infusion of either ang II (490 ng/kg/min) or an isotonic vehicle (sodium chloride/acetic acid solution) for sham mice. In some experiments, hypertension was prevented by coadministration of hydralazine and hydrochlorothiazide as previously described.
11
Response of human T cells and dendritic cells to ang II: Two experimental approaches were employed to examine the direct effects of ang II on human immune cells. In the first, human T cells were isolated from the blood of normotensive volunteers using magnetic sorting and 10 6 cells were exposed to anti-CD3 + coated culture plates with anti-CD28 (2 μg/ml) added to the media for 3 days in the presence or absence of 0.1 μMol/L of ang II. Intracellular staining was employed to identify cells containing IFN-γ, IL-17A and forkhead box P3 (FoxP3) as previously described. 12 As a second approach, human monocytes were differentiated to dendritic cells in the presence of GM-CSF and IL-4 with and without addition of 0.1 μMol/L ang II. These cells were then co-cultured with CFSE-labeled T cells from the same volunteer at a ratio of 1 dendritic cell to 10 T cells. Flow cytometry: Flow cytometry was performed on single cell suspensions of thoracic lymph nodes, the right kidney and the descending thoracic aorta as previously described. Please see the on-line supplement for complete description of the methods employed.
Studies of circulating T cells in humans:
RESULTS
Effect of angiotensin II-infusion on blood pressure of humanized mice: The blood pressure of humanized mice increased to 162 mmHg following two weeks of ang II infusion when compared to mice that were exposed to a sham infusion ( Figure S2 ). Co-administration of hydralazine and hydrochlorothiazide reduced blood pressure to 112 ± 0.5 mmHg. (Table 2 ).
Effect of angiotensin II-induced hypertension
There were relatively few CD69 + T cells in the kidney and these were not changed by ang II infusion (Table S1) (Table S1 ). There were non-significant trends for increases in these cells in the kidney ( Figure 4A ) and the aorta ( Figure 4B ). In the lymph nodes, ang II infusion caused a significant increase in this 15 we considered the hypothesis that endogenous ang II might affect human T cell production of cytokines. Co-incubation human T cells with ramipril (1 μMol/L), however, had no effect on production of any cytokines measured (data not shown). In another experiment, we cultured human monocytes for 7 days with granulocyte/macrophage colony stimulating factor (GM-CSF) and IL-4 in the presence and absence of ang II (0.1 μMol/L). The resultant differentiated dendritic cells were then cultured with CFSE-labeled T cells from the same donor. As shown in figure 5E and S3, there was no effect of ang II on the ability of human DCs to drive T cell proliferation. Moreover, ang II did not directly stimulate the accumulation of isoketal-protein adducts in human DCs, as evidenced by intracellular staining with the isoketal adduct antibody D11 ( Figure 5F ).
Effect of angiotensin II
Inflammatory profile of circulating T cells in humans with and without hypertension:
To further characterize the effect of hypertension on T cell phenotype, we studied 20 normotensive and 20 hypertensive humans, matched for sex, age and BMI. Hypertensive patients had significantly higher office blood pressures and both systolic and diastolic blood pressures as measured by ambulatory blood pressure monitoring. Plasma renin and aldosterone levels were elevated in the hypertensive group compared to the normotensive subjects. As shown in figure 6A and 6B, the percent of both CD4 with hypertension, and pointed out that these appeared to be lymphocytes and monocytes. 16 We found that blood levels of IL-17A are three-times higher in diabetic humans with hypertension as compared to those without hypertension. 6 Herrera et al showed that the T cell suppressing agent mycophenolate mofetil lowers blood pressure in humans with rheumatoid arthritis or psoriasis. 17 Recently, Yoshida et al demonstrated that the TNF-α antagonist infliximab lowers blood pressure in patients with rheumatoid arthritis. 18 Of note, the incidence of hypertension is increased in humans with such autoimmune diseases. In the present study, we also found an increase in the percent of circulation memory The accumulation of human T cells in the kidney of humanized mice is similar to the accumulation of renal T cells observed by Youn et al and parallels similar increases that we and others have observed in mice with experimental hypertension. 21, 23, 24 It is likely that cytokines released from T cells in the kidney promote sodium and volume retention and lead to renal damage. We recently found that IFN-γ modulates phosphorylation and activation of the Na-K-2Cl cotransporter, Na-Cl cotransporter, and Ste20/SPS-1-related proline-alanine-rich kinase in response to long-term ang II infusion. 25 In this study, we established an important role of IL-17A and IFN-γ in modulating expression of Na/H-exchanger isoform 3 and the motor myosin VI in the proximal tubule and in the anti-natriuretic and anti-diuretic effects of ang II.
The propensity of human T cells to accumulate in the kidney supports the notion that these cells might contribute to human hypertension in a similar fashion.
It is also of interest that we observed a striking increase in human T cells in the thoracic lymph nodes of the humanized mice in response to ang II infusion. This was paralleled by an increase in cells bearing the memory cell marker CD45RO. Memory cells persist after an initial expansion of a naïve pool, and it is therefore logical to conclude that the increase in total T cells and memory T cells in the lymph nodes was due to proliferation and expansion in response to ang II infusion not observed in the sham infused mice. We cannot exclude the role of chemokines and adhesion molecules that might also have been increased by ang II in the lymph nodes and kidneys of the humanized mice that could have attracted the human cells to these organs. It is notable that while prevention of hypertension using hydralazine and hydrochlorothiazide reduced the total number of T cells in the lymph nodes, the number of memory T cells in the lymph nodes increased. This might reflect differences in the effect of hypertension as well as direct effects of angiotensin II on trafficking of memory cells in secondary lymphoid organs.
Using strict flow minus one gating criteria, we also observed an increase in CD3 + cells lacking either CD4 or CD8 surface markers, particularly in the lymph nodes. We have observed a similar increase in double negative murine T cells in hypertensive mice. It is conceivable that these double negative T cells are actually CD4 + cells that have lost surface CD4, as has been observed during intense T cell stimulation with phorbol esters or myxoma virus. 26, 27 We have previously proposed that mild elevations in blood pressure, such as observed in prehypertension, lead to formation of neoantigens that activate T cells which exacerbate vascular remodeling and renal dysfunction, leading to further elevations of blood pressure. 28 Our current finding that preventing the initial elevation in blood pressure prevents human T cell activation is in keeping with this concept. Our results also indicate that ang II does not directly activate human T cells. We and others have previously shown that T cells contribute to salt-sensitive hypertension in rats and mice. 1, 29 These conditions are associated with suppression of ang II production, indicating that this octapeptide is not needed for this action of immune cells in hypertension. Our results with pharmacological prevention of hypertension should be viewed with some caution however because pharmacologic agents can have off target effects that might directly inhibit T cell function. As an example, we previously showed that hydralazine potently inhibits the NADPH oxidase, 30 and thus might prevent formation of immunogenic isoketal-protein adducts independent of its blood pressure lowering effects. To avoid the confounding effects of such agents, we examined the direct effect of ang II on both human T cells and human DCs however failed to observe a change in the production of inflammatory cytokines or the T regulatory cell transcription factor FoxP3. In preliminary experiments, we also found that norepinephrine did not enhance the ability of DCs to drive T cell proliferation.
Taken together, we view these findings as suggesting that human immune cells likely take cues from other tissues in vivo to become activated in hypertension. In keeping with this, we recently found chronic vascular oxidative stress induces activation of both DCs and T cells in mice, likely by generating isoketals within the vessel that are taken up by DCs. 31 It is possible therefore that vascular oxidative stress associated with hypertension promotes human T cell activation.
We encountered several limitations in the present study that precluded in-depth study of these mice. We found that these mice did not tolerate the two surgeries needed for implantation of telemetry units for blood pressure measurement and subsequent osmotic minipump placement, and therefore relied upon tail cuff measurement of blood pressure. Our studies should also be interpreted with caution because it is unclear how effectively human T cell receptors interact with mouse adhesion molecules and chemokines. It is possible, for example, that vascular adhesion molecules in humans might more avidly attract activated T cells to vessels than we observed in the humanized mouse. The humanized mouse also presents a limited window of time, ranging from 4 to 12 weeks after reconstitution with human tissues before graft vs. host disease develops, and therefore longer-term hypertensive challenges are problematic. In our studies, none of the mice exhibited signs of graft vs. host disease, such as weight loss, diarrhea or hair loss. Because human T cell expansion did not occur in the sham infused animals, we do not believe that the T cell activation observed in the ang II-treated group was due to graft vs. host disease.
PERSPECTIVES
This is the first study to demonstrate that human T cells respond to a hypertensive stimulus such as ang II by expanding and infiltrating the kidney and vasculature. Our results might also help explain the striking benefit of blood pressure correction observed in the recent SPRINT trial. 32 It is conceivable that intensive blood pressure lowering by any means can prevent activation of human immune cells and therefore reduce cardiovascular inflammation. Beta -blockers (%) 0 (0%) 12 (60%) Calcium channel blockers (%) 0 (0%) 14 (70%) Alpha -blockers (%) 0 (0%) 6 (30%) Diuretics (%) 0 (0%) 9 (45%) Statins (%) 1 (5%) 9 (45%) 
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